Top 5 Defensive Stocks To Watch Right Now

We select stocks based on the known investing strategy of select legendary investors. This stock idea scores a 100% rating based on the approach of value investor Benjamin Graham, by John Reese, editor of Validea.

HollyFrontier (HFC) is a petroleum refiner, which produces light products, such as gasoline, diesel fuel, jet fuel, specialty lubricant products, and specialty and modified asphalt.

To meet the Graham criteria, the stock can be neither a technology nor financial company, and therefore this methodology is applicable.

Under this approach, the investor must select companies of adequate size. This includes companies with annual sales greater than $340 million. HFC's sales of $20,358.9 million, based on trailing 12 month sales, pass this test.

The current ratio must be greater than or equal to two. Companies that meet this criterion are typically financially secure and defensive. HFC's current ratio of 2.37 passes the test.

Top 5 Construction Stocks To Buy Right Now: Freshpet Inc (FRPT)

Freshpet Inc is a company which provides fresh food for pets, such as dogs and cats. The Company provides meats- based recipes, such as chicken, beef, lamb and salmon; fruits and vegetables, such as carrots, peas and leafy green vegetables, and high-fiber grains, such as brown rice, oats and barley.

Freshpet produces its food products in Pennsylvania, United State. The Company provides food packed with vitamins, proteins and amino acids.

Advisors' Opinion:

• [By MONEYMORNING]

  Based in Ladson, S.C., Force Protection Inc. (Nasdaq: FRPT) met the Defense Department's need with two series of armored vehicles, the Buffalo and Cougar, which were designed to detect IEDs and landmines and serve as personal transports.

Top 5 Defensive Stocks To Watch Right Now: Arris Group Inc(ARRS)

Arris Group, Inc. develops, manufactures, and supplies telephony, data, video, construction, rebuild, and maintenance equipment for the broadband communications industry worldwide. The company operates in three segments: Broadband Communications Systems (BCS); Access, Transport, and Supplies (ATS); and Media and Communications Systems (MCS). The BCS segment provides VoIP and high speed data products, including CMTS edge routers, 2-line residential EMTA, multi-line EMTA for residential and commercial services, wireless gateway, and high speed data cable modems; video/IP products comprising CMTS edge routers, broadband and universal EdgeQAM, and whole home gateway and media players; and video processing products, such as switched digital video systems, digital video encoders, transcoders, transraters, and statistical multiplexers. The ATS segment offers hybrid fiber-coaxial plant equipment products comprising headend and hub products, optical transmitters, optical amplifiers , optical repeaters, optical nodes, WiFi access points, ePON optical network units and line terminals, RF over glass optical network units, and radio frequency amplifiers; and infrastructure products for fiber optic or coaxial networks, which include cable and strand, vaults, conduit, drop materials, tools, connectors, and test equipment. The MCS segment provides media, delivery, and monetization platform products, such as video on demand management and distribution, and linear and advanced advertising; operations management systems comprising network and service assurance, and mobile workforce management; and fixed mobile convergence platform products, such as mobility application servers for continuity of services in wireless and PacketCable networks, and voice call continuity application servers for continuity of services in IP multimedia subsystem networks. The company offers its services to cable system operators. Arris Group, Inc. was founded in 1969 and is headquarter ed in Suwanee, Georgia.

Advisors' Opinion:

• [By Lee Jackson]

  Arris Enterprises Inc. (NASDAQ: ARRS) got hit when press reports indicated that Apple may be working with Time Warner Cable and other companies on a new set-top box. The Jefferies team do not know the specifications of the device. It still may use “HDMI pass through” architecture like XBox One (and therefore will still require a cable STB to support cable content). That would bode well for Arris. The Jefferies target is lifted to $30. The Thomson/First Call estimate is $28.05. Arris closed on Friday at $27.87.

Top 5 Defensive Stocks To Watch Right Now: Vanda Pharmaceuticals Inc.(VNDA)

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. Its lead product includes Fanapt for the acute treatment of schizophrenia in adults. The company is also developing Tasimelteon, an orphan medicinal product for the treatment of sleep and mood disorders, including non-24 hour sleep/wake disorder in blind individuals without light perception. It also intends to initiate a Phase IIb/III clinical trial of tasimelteon in patients with major depressive disorder; and conduct additional clinical trials to support the use of tasimelteon as a circadian regulator. The company was incorporated in 2002 and is headquartered in Rockville, Maryland.

Advisors' Opinion:

• [By Nathalie Tadena]

  Among the companies with shares expected to actively trade in Friday’s session are Vanda Pharmaceuticals Inc.(VNDA), Kimberly-Clark(KMB) and Cell Therapeutics(CTIC).

• [By Paul Ausick]

  Stocks on the Move: Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) is up 95.8% at $13.29 on FDA recommendation for approval of its sleep drug for the blind. Sarepta Therapeutics Inc. (NASDAQ: SRPT) is down 64.3% at $13.05 following an FDA rejection of the company�� bid to fast-track muscular dystrophy drug. U.S. Airways Group Inc. (NYSE: LCC) is up 1.1% at $23.53 after reaching an agreement with the Department of Justice that will let the company go ahead with its American Airlines merger.

• [By Roberto Pedone]

  Another biotechnology player that looks poised to trigger a big breakout trade is Vanda Pharmaceuticals (VNDA), which is focused on the development and commercialization of clinical-stage drug candidates for central nervous system disorders. This stock has been on fire so far in 2013, with shares up a whopping 258%.

  If you take a look at the chart for Vanda Pharmaceuticals, you'll notice that this stock has recently broke out above some near-term overhead resistance levels at $12.34 to $12.66 a share with solid upside volume. So far, this breakout has held and now shares of VNDA are quickly moving within range of triggering an even bigger breakout trade.

  Traders should now look for long-biased trades in VNDA if it manages to break out above its 52-week high at $13.30 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action 908,467 shares. If that breakout hits soon, then VNDA will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that breakout are $15 to $17 a share.

  Traders can look to buy VNDA off any weakness to anticipate that breakout and simply use a stop that sits right below some near-term support at $12 a share. One could also buy VNDA off strength once it takes out $13.30 a share with volume and then simply use a stop that sits a comfortable percentage from your entry point.

Top 5 Defensive Stocks To Watch Right Now: Stemline Therapeutics Inc (STML)

Stemline Therapeutics, Inc. (Stemline), incorporated on August 8, 2003, is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics that target both cancer stem cells (CSCs) and tumor bulk. The Company is developing two clinical-stage product candidates, SL-401 and SL-701, for which it holds global marketing rights. The indication for SL-401, a biologic-drug conjugate, is acute myeloid leukemia (AML). The indications for SL-701, a synthetic peptide vaccine, are pediatric and adult brain cancer. It has a platform, StemScreen, for the discovery of CSC-targeted compounds, from which it has discovered or validated several of its clinical and preclinical product candidates. Stemline�� StemScreen consists of StemScreen-1 and StemScreen-2 for the identification of CSC-directed compounds.

SL-301 is a small molecule gamma-secretase inhibitor that inhibits Notch, a pathway expressed by CSCs and tumor bulk of multiple cancer types. SL-101 is a monoclonal antibody-based (mAb -based) compound that targets CD123 and has shown in vitro activity against certain hematologic cancers. SL-201 is a small molecule active against certain hematologic and solid tumor types. SL-601 is a mAb-based compound that targets a cell surface marker on bladder CSCs, which is also expressed on a variety of other solid tumor types. It has also in-licensed certain intellectual property directed to mAb-based therapeutics to validated oncology targets, including Glypican-3, Tie-1, CD133, Frizzled, Smoothened and Patched.

SL-401 - An IL-3R-Directed Compound Targeting Cancer Stem Cells and Tumor Bulk

SL-401 is a clinically active biologic-drug conjugate consisting of human interleukin-3 (IL-3) genetically linked to a truncated version of diphtheria toxin. SL-401 targets the IL-3 receptor (IL-3R), which is overexpressed on both the CSCs and tumor bulk of multiple hematologic cancers, including AML. SL-401 has demonstrated preclinical in vit! ro and in vivo activity against both leukemia blasts (which includes tumor bulk) and CSCs of a range of human leukemia cell lines and primary leukemia cells from patients.

SL-701

SL-701 is a clinically active synthetic peptide vaccine that targets several epitopes on CSCs and tumor bulk of brain cancer. In two completed Phase 1/2 clinical trials, SL-701 demonstrated single agent anti-tumor activity in pediatric patients with newly diagnosed brainstem glioma (BSG) and other high-grade gliomas (HGGs) and in adult patients with refractory or recurrent GBM, and other HGGs.

StemScreen-1

StemScreen-1 is a drug discovery platform designed to identify CSC-targeted compounds based on the isolation of CSCs and evaluation of CSC gene expression profiles. CSCs are isolated from primary tumor tissue or cell lines, and then subjected to gene expression analysis using a variety of technologies, including microarray. A control tissue, such as normal bone marrow is analyzed as a comparator against the gene expression profile of the isolated CSCs. These data are then interfaced with an information base of compounds and their mechanisms of action (that is which gene products and pathways they impact). It has utilized StemScreen-1 to discover a number of its preclinical drug candidates. These include SL-201, SL-301, and SL-601. In addition, SL-401 demonstrated activity against CSCs as determined by both an in vitro colony formation and in vivo animal implantation assay, thereby validating certain StemScreen-1 anti-CSC assays.

StemScreen-2

StemScreen-2 is a high throughput drug discovery platform it is developing to discover anti-CSC compounds. StemScreen-2 utilizes a cell-based assay that can track and follow CSCs in their natural state during high throughput screening. In particular, StemScreen-2 utilizes a CSC-specific promoter linked to a reporter as a method for identifying and following CSCs in their native environment of surrounding tumor b! ulk. In t! his way, StemScreen-2 enables the identification of compound hits, in a high throughput manner, with anti-CSC activity.

The Company competes with Boston Biomedical, Inc., Eclipse Therapeutics, Inc., OncoMed Pharmaceuticals, Inc., Verastem, Inc., Astellas Pharma US, Inc., Boehringer Ingelheim GmbH, Dainippon Sumitomo Pharma Co. Ltd., Geron Corp., GlaxoSmithKline plc, ImmunoCellular Therapeutics, Ltd, Macrogenics Inc., Amgen, Inc., Pfizer Inc., Roche Holding AG, Sanofi U.S. LLC., Cyclacel Pharmaceuticals, Inc., Sunesis Pharmaceuticals Inc., Clavis Pharma ASA, Ambit Biosciences Corporation, Celgene Corporation, Eisai Co. Ltd., Celator Pharmaceuticals, Inc., Merck & Co., Inc., Eisai Co., Inc., Roche Holding AG, Novartis AG and Celldex Therapeutics, Inc.

Advisors' Opinion:

• [By Keith Speights]

  Best-performing biotech IPO
  Stemline Therapeutics� (NASDAQ: STML  ) has only traded publicly this year, but what a year it's been. The stock's performance ranks Stemline as the best-performing biotech IPO so far in 2013. This week has been pretty good also, with shares moving up by 28%.

• [By Jay Silverman]

  Some of the biggest leaders in that field, and there have been dozens in fields, if not more this year, such as Bluebird (BLUE) and Stemline Therapeutics (STML) and have all pulled back to significantly lower levels; even below, in Bluebird's case, the price that had actually opened up as an IPO, even though it's above its IPO price.

• [By David Zeiler]

  3. Stemline Therapeutics Inc. (Nasdaq: STML): This biotech develops drugs that target cancer stem cells and tumors. Stemline went public January 29 at $10 a share and rose just 11.78% on its first day. But STML has climbed steadily since, and currently trades at $37.46, up 274.6% from its IPO price.